|
|
Line 330: |
Line 330: |
|
| |
|
| ==Toxic== | | ==Toxic== |
| | |
| | === 2023: [https://pubmed.ncbi.nlm.nih.gov/37089248/ Biomarkers of Electronic Nicotine Delivery Systems (ENDS) use.] === |
| | * Highlights |
| | ** Biomarkers play an essential role in characterizing the health risks of ENDS. |
| | ** Identification of biomarkers specific to ENDS remains a challenge. |
| | ** Levels of many toxicant biomarkers in ENDS users do not differ from non-users. |
| | ** Exclusive ENDS users show lower concentrations of toxicant biomarkers compared with smokers. |
| | ** In studies on ENDS, it may be beneficial to use a panel of biomarkers |
| | * The biomarker levels of many tobacco-related toxicants measured in biological samples collected from ENDS users did not differ significantly from non-users, except for nicotine metabolites and a small number of biomarkers of exposure to volatile organic compounds and tobacco-specific tobacco nitrosamines. Several studies have shown that while exposed to nicotine, long-term exclusive ENDS users showed significantly lower levels of toxicant biomarkers than cigarette smokers. |
| | * Goniewicz ML. Addict Neurosci. 2023 Jun;6:100077. doi: 10.1016/j.addicn.2023.100077. Epub 2023 Feb 26. PMID: 3708924 |
|
| |
|
| 2021: Screening of different cytotoxicity methods for the assessment of ENDS toxicity relative to tobacco cigarettes | | 2021: Screening of different cytotoxicity methods for the assessment of ENDS toxicity relative to tobacco cigarettes |